This growing and emerging list of panels is based off MSD’s SARS-CoV-2 Panel 2 which was selected for the standard binding assays for immunogenicity assessments for all funded Phase III clinical trials by US-government initiative – Operation Warp Speed. There are over 35 SARS-CoV-2 variants including the Alpha, Beta, Gamma, Delta, Lambda and Mu variants in panels for human and mice samples. MSD has launched a new, ultrasensitive S-PLEX multiplex panel consisting of three key biomarkers associated with neurological disease research applications: GFAP. NEW V-PLEX® Serology Panels for SARS-CoV-2 VariantsĢ0 different multiplex serology assays available for antibodies to Spike antigens related to the SARS-CoV-2 virus. The MESO QuickPlex SQ 120 is a compact, affordable multiplexing imager with exceptional performance. The SECTOR S 600 is ideal for applications requiring high information content and high throughput.

MSD offers instruments to fit every application, budget, and research environment. MSD’s proprietary MULTI ARRAY technology enables researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. The MSD platform shows promise for simultaneous quantitation of the antibody responses to four HPV vaccine types in a high-throughput manner.ĮLISA HPV antibodies Meso Scale Discovery Multiplex Serology.Meso Scale Discovery (MSD) is a global leader for innovative assays and instruments for the measurement of molecules in biological samples. Quantitative analysis however showed a good correlation between concordant samples by both assays (ρ ≥ 0.6). There was moderate agreement (κ = 0.38-0.54) between M4ELISA and cLIA, with antibody detection for each of the 4 types more frequent with M4ELISA. Long-term stability of the plates extended to about 7 months from the time plates was received in the laboratory after printing. This information is provided by SPC as a way of sharing the latest severe weather diagnostic techniques with local forecasters. The dynamic range of the assay was about 1000 fold, with assay variability under 25% for each of the four vaccine types. Using a VLP coating concentration of 80 μg/ml with BSA provided the most robust RLU signal for all types. Results of the M4ELISA were compared to competitive Luminex Immunoassay (cLIA) on n = 4454 sera from a predominantly unvaccinated cohort.

Cut-off values using children's sera were established using 99% RLU limits based on the 4-parameter Johnson Su best fit curve. Dynamic range, precision, and stability of pre-printed plates were determined using a panel of previously characterized sera. Three-point titrations and the parallel line method were used to calculate antibody levels. MSD prepared the plates in the 7-spot/well format, using the purified VLPs (4 spots) and PBS+BSA pH7.4 (3 blank spots). We used the Meso Scale Discovery (MSD) electrochemiluminescence based detection platform to develop a multiplex direct virus-like particle (VLP) ELISA to detect antibodies to HPV 6, 11, 16, and 18 with a protocol developed for detection using the SI 6000 imager (M4ELISA). An ideal assay platform would allow multiplex type-specific detection with minimal sample requirement. Reliable antibody based-assays are needed to evaluate the immunogenicity of current vaccines, impact of altered dosing schemes or of new vaccine formulations.

Meso scale diagnostics